Promising new cocktail takes on tough lung cancer
NCT ID NCT07358676
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests a new treatment for people with extensive-stage small cell lung cancer who have not had treatment before. The approach combines the drug bemotuzumab with standard chemotherapy and another drug called anlotinib, followed by chest radiation. The goal is to see if this combination can delay cancer growth and be safe for about 25 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a targeted drug combo outperform standard chemo for tough lung cancer?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New drug cocktail aims to shrink tough lung cancers